Belzutifan is an inhibitor of HIF-2α. It’s used to treat RCC that’s connected to VHL and it attacks tumor cells that need low oxygen.
It comes in 40 mg film-coated tablets, with a recommended dose of 120 mg taken once daily. These come in bottles holding 90 of those tablets.
